The 14 analysts offering 12-month price forecasts for Blueprint Medicines Corp have a median target of 104.50, with a high estimate of 122.00 and a low estimate of 77.00. The median estimate represents a -0.32% decrease from the last price of 104.84.
The current consensus among 15 polled investment analysts is to Buy stock in Blueprint Medicines Corp. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $9.26
Reporting Date Oct 29
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.